levels (secondary outcomes). Full/partial remission was defined as 0.5/ 1.0 g/day for proteinuria, 5/ 8 for SLEDAI and 25/ 50 IU/mL for anti-dsDNA levels. We further assessed flares, infections, malignancies and procedure-related adverse events.
Results. Short-term IAS ( 1 year) resulted in a significant reduction of proteinuria (9.2 6 3.7 to 2.3 6 2.4, P ¼ 0.0001), disease activity (SLEDAI 19 6 8 to 4 6 2, P ¼ 0.0004) and dsDNA levels (168 6 205 to 45 6 34, P ¼ 0.001).
In patients without remission after 1 year (n ¼ 5), prolonged IAS decreased proteinuria from 4.3 6 2.4 to 0.5 6 0.4 g/day, P ¼ 0.02. At the end of observation, complete remission in proteinuria was achieved in seven patients (64%) and partial remission in two (18%) additional patients. One patient flared and was discontinued; in all other patients, disease activity and anti-dsDNA stabilized at remission levels. Flares (0.28 6 0.30) and infections (0.66 6 0.70 per patient/year) were relatively uncommon; no malignancies, anaphylactic or orthostatic adverse events were observed.
Introduction
Pathogenic autoantibodies are a hallmark of Systemic lupus erythematosus (SLE). They bind directly or via formation of immune complexes (IC) to cells and tissues, inducing complement activation and severe inflammation in the affected organ, such as the kidneys [1] . Among these IC-forming antibodies are anti-double-stranded DNA antibodies (anti-dsDNA), which are associated with lupus nephritis [1] [2] [3] [4] [5] [6] [7] [8] [9] . Inhibiting the production of, or directly removing, such pathogenic autoantibodies should prevent their pathogenetic consequences. In fact, SLE therapy in general, and immunosuppression in particular, aims at interfering with autoantibody and IC formation. In severe SLE with major organ involvement, therapy initially aims at halting disease progression and reducing disease activity (induction phase); ultimately, the goal is to stabilize disease activity at low levels (maintenance phase). Intravenous pulse cyclophosphamide (IVCP) therapy continues to be the standard treatment for induction therapy in severe SLE with major organ involvement according to the EULAR (European League Against Rheumatism) recommendations [10] . It is effective in many, but not all, patients [11] , encompasses a wide array of adverse events and is contraindicated in some situations, such as acute infection [12] [13] [14] [15] . Therefore, alternative approaches have been sought. Mycophenolate mofetil (MMF) is established as a maintenance therapy of lupus nephritis and increasing evidence suggests its efficacy also in the induction phase, but a prospective head-to-head trial could not demonstrate superiority over IVCP [10, 16] . Given the pathogenetic effects of auto-antibodies, B-cell depletion by monoclonal antibodies like rituximab came into the focus of interest. Meanwhile, a large body of evidence showed benefit, but, nevertheless, two controlled clinical trials could not reach their primary goals [17, 18] .
Extracorporeal treatment options like immunoadsorption (IAS) do not directly aim at B cells, but on their products: they remove (auto-) antibodies and IC and have been successfully applied in acute life-threatening situations of SLE [19] [20] [21] . Their benefit lies in the fast mode of action, the flexibility to adjust the frequency of therapeutic sessions (and the processed plasma volume) and the option to suspend them for a time when optimal B-cell function is needed. IAS allows for the specific clearance of immunoglobulins (Ig) and IC [22] [23] [24] [25] while neither removing other plasma proteins nor necessitating substitution with blood products [19, 26, 27] .
Previous reports have shown short-term efficacy and biocompatibility of IAS in SLE [19, 20, 22, 28, 29] , but no information on long-term outcome beyond the first year of treatment is available. In addition, the issue of infections and malignancies has not been analysed under prolonged treatment: since immune system function is altered by removal of Ig under IAS, the defense against infections and malignancies of any kind might be impaired.
Prospective randomized controlled trials (RCT) on IAS in SLE are lacking and would be preferable [30] . But given that most patients entering this procedure have failed multiple therapies including cyclophosphamide, have contraindications to certain treatment modalities or have no alternative in the light of negative clinical trials on such alternatives [31] , it is difficult to study severe SLE in RCTs because of the unavailability of alternative therapies in the comparator arm and because of the heterogeneity of the disease. Therefore, observational studies involving patients with nephritis have often been a prelude to RCTs.
In the present study, we identified patients with lupus nephritis, who were treated with IAS at our centre and followed them for up to 10 years. Prolonged IAS (>1 year) added therapeutic benefit and led to sustained remission in a considerable percentage of formerly highly active refractory patients. In addition, IAS was safe with respect to infections, malignancies and adverse events.
Materials and methods

Study design
In this long-term observational study (LOS) [30] [31] [32] , all data were prospectively collected according to predefined IAS protocols, standardized laboratory analyses and established routine clinical care to obtain complete information [20] . The analysis of the patients' data has been approved by the local ethics committee.
End points. Improvement in proteinuria was defined as the primary end point as it is the main feature of renal disease and regarded as the most objective system to study [31] . Reductions in the SELENA version of the SLE Disease Activity Index (SLEDAI) [33] and in pretreatment, antidsDNA levels were defined as secondary end points. A reduction by at least 50% was considered a major response (R50), a decrease !20% was considered a minor response (R20) [20] .
Responders. After 3 months of IAS, efficacy was assessed: patients who showed an R20 in at least two of three outcomes (i.e. proteinuria, SLEDAI and anti-dsDNA levels) were regarded as responders and offered a 9-month extension [20] . After 12 months, patients were reassessed: responders (!R20 in !2 outcome measures compared to 3-month results, or ! R50 in all three outcome measures compared to start of IAS) were offered a prolongation. The end of observation (EoO) was defined as the time point at which patients had undergone 10 years of IAS treatment, or 1 January 2009, whichever came first. If IAS was stopped earlier, the last observation under IAS was carried forward.
Remission criteria. In addition to the response criteria, we defined a complete remission as follows: proteinuria 0.5 g/day, SLEDAI 5 and pretreatment anti-dsDNA abs 25 IU/mL [34] . Partial remission was defined as proteinuria 1 g/day, SLEDAI 8 and anti-dsDNA levels 50 IU/mL.
SLE disease activity and organ damage
As recommended for LOS [31] , we collected global information on SLE activity as integrated in the (SELENA-) SLEDAI [33] , the SLE Index Score and the European Consensus Lupus Activity Measure scores [35, 36] . For assessment of SLE flares, we used the SELENA definition [33] . Disease-related damage was analysed by the SLE International Collaborating Clinics/ACR Damage Index (SLICC/ACR) [37] .
Patients, indication for IAS and concomitant medication
IAS was started as a rescue therapy in patients with high disease activity and severe progressing organ involvement. A total of 11 patients underwent prolonged IAS treatment: They fulfilled the ACR criteria for SLE, had histologically proven lupus nephritis, nephritic urinary sediment and proteinuria !0.5 g/day (Table 1 ) [2] .
Patients were started on IAS if standard treatment failed or was contraindicated [10, 20, 28] . In line with the EULAR recommendations, the goal was to administer IVCP for active severe lupus nephritis; three patients also had active involvment of the central nervous system (CNS; neurolupus), which adds a second indication for cyclophosphamide (Pat. #4, #5, #6; Tables 1 and 4) [10] .
In the cohort studied, six (55%) patients were subjected to IAS because cyclophosphamide was not sufficient to halt progression of proteinuria. In five (45%) patients, IVCP was contraindicated: two patients had severe leucopenia (Pat. #1 and #2), one patient had received high cumulative cyclophosphamide doses and was started on IAS in combination with preexisting stable MMF therapy (Pat. #8), one patient had active tuberculosis (Pat. #10) and one patient refused immunosuppression (Pat. #5; Tables 1 and 4 ).
All patients receiving IVCP at the start of IAS therapy were switched to azathioprine (AZA) or MMF when clinically feasible. For patients receiving immunomodulators before the start of IAS, drug and dosage were kept constant as were angiotensin converting enzyme (ACE) inhibitors/AT-II receptor antagonists (AT-II-RA). Glucocorticoids were tapered if clinically feasible.
Immunoadsorption
IAS is employed as a compassionate treatment at our tertiary care centre [19, 20, 22, 28, [38] [39] [40] [41] . The three different high-affinity columns used can bind human Ig and IC via biological interactions but use different ligands, namely sheep Ig, staphylococcal protein A or synthetic peptide Gam146, respectively [22] [23] [24] . All are similarly effective in SLE [38] . Of the patients reported herein, 10 were started on Ig columns (Ig-TherasorbÒ by Miltenyi Biotec), and 1 on Gam columns (GlobaffinÒ by Fresenius Medical Care).
IAS was performed as described [20, 39, [42] [43] [44] . In brief, 2.5-fold of the calculated plasma volume (i.e. 6000-8000 mL) was processed during a single-treatment session via a venovenous vascular access. Two sessions of IAS within 3 days (¼one cycle) were performed according to clinical demands; during the prolonged IAS program, one cycle was performed every 3 weeks.
Assessment, laboratory studies
All patients were followed prospectively at one centre and assessed before each IAS session: the patients' history was taken, a clinical examination was performed and blood samples were drawn. Complete blood count, erythrocyte sedimentation rate, serum C-reactive protein, as well as serum creatinine, albumin and electrolytes, antinuclear antibodies, anti-dsDNA abs (RIA), C3c, C4 and urinalysis were determined by standard laboratory methods.
Adverse events and infections
We recorded all malignancies, allergic reactions and symptomatic hypotensive or orthostatic dysregulation. Infections were affirmed by needle aspiration, blood, urine and/or stool cultures or by imaging techniques whenever clinically suspected. For the detection of viral infections, complement fixation test, indirect immunofluorescence, enzyme immunoassays and/or polymerase chain reaction were employed. Infections were subcategorized as either severe (necessity of hospitalization and/or intravenous therapy) or minor (requiring oral therapy).
Statistical analysis
Group results were expressed as mean AE SD and/or percentage of initial value at start of observation unless stated otherwise. Paired Student's t-test and Student's t-test were used for comparison of individual paired values, group values and discriminatory parameters. Wilcoxon's matched pairs test was used if the distribution was not Gaussian. Analysis of variance for repeated measurements was used for three or more dependent groups, followed by a Bonferroni's multiple comparison test. All statistical analyses were performed with GraphPad Prism 3.0.
Results
Short-term IAS ( 12 months)
Proteinuria and renal function. After 12 months of IAS, there was a significant decrease in proteinuria ( Figure 1 and Table 2 ): all patients had at least an R20; 82% showed a reduction by !50%. At the end of short-term IAS, three (27%) patients met the criteria for complete remission and an additional three (27%) met those for partial remission (Table 3A) . Renal function improved as indicated by a significant increase in creatinine clearance and a decrease in serum creatinine levels ( Table 2) .
Global disease activity. Under short-term IAS, all global scores of disease activity improved, leading to a significant reduction of the SLEDAI and an improvement of the immunological markers of disease activity, indicated by a decrease in anti-dsDNA and an increase in serum complement levels (Table 2) . At the end of short-term IAS, all patients were-at least-in partial remission with regard to global disease activity (Table 3A) .
Prolonged IAS (!1-10 years) Primary end point: proteinuria. Eleven patients entered the prolonged IAS programme and underwent 6.4 AE 3.5 At the EoO, seven (64%) patients were in complete remission and an additional two (18%) in partial remission. One nonresponder is discussed below (Pat. #7). Analysing the whole group, mean proteinuria could be stabilized within remission limits ( Figure 1 and Table 3 ).
In order to analyse whether prolonged IAS in fact provides additional therapeutic benefit, those patients who did not meet remission criteria after 1 year were analysed in detail (Non-Rem group).
Patients not reaching remission after short-term IAS (NonRem Group). Five patients did not meet the criteria for complete or partial remission with respect to the primary outcome proteinuria after 1 year of IAS. Under prolonged IAS, mean proteinuria in these patients decreased from 4.3 AE 2.4 to 0.5 AE 0.4 g/day (P ¼ 0.02), constituting a significant Fig. 1 . Decrease in proteinuria, overall disease activity (SLEDAI) and pretreatment anti-dsDNA-antibodies under IAS therapy. IAS was applied in SLE patients refractory to therapy with immunosupressants (such as cyclophosphamide) or when immunosupression was refused or contraindicated. Shortterm IAS up to 1 year effectively reduced proteinuria, disease activity and dsDNA levels (white columns). Under prolonged IAS (up to 10 years of therapy; black columns), proteinuria, SLEDAI and pretreatment anti-dsDNA-antibodies could be stabilized at levels meeting the remission criteria (light gray boxes indicate values defined for partial remission and darker gray boxes indicate complete remission). Values for patients undergoing full 10 years of therapy are also given in an additional subgroup analysis (right column, 10 years). increase in serum albumin levels. Also in this group, global disease activity (SLEDAI) decreased from 5 AE 2 to 2 AE 2 (P < 0.001), while serum C3c and C4 complement normalized by the EoO (Table 3B) .
Secondary end points: global disease activity and antidsDNA levels. At the end of short-term IAS, patients had attained mild disease activity. With prolonged IAS, disease activity could be stabilized and all but one patient reached at least partial remission for both disease activity and antidsDNA-levels at EoO (Table 3 and Figure 2 ). This stabilization of disease activity is also indicated by a reduced number of flares compared to short-term IAS (0.28 AE 0.30 versus 0.64 AE 0.64, P < 0.05) ( Table 5 ). In general, the incidence of flares is considered 0.65 per patient per year of follow-up [45] . Comparing our patients with a similarly active and similarly treated cohort (67 MMF-treated patients, mean SLEDAI of 4.8 AE 2.3), where the same definition of flare was used, we observed a considerable lower number under prolonged IAS (0.28 versus 0.89 flares per patient year) [46] .
Responders and nonresponders at EoO, damage score. At the EoO, six (55%) patients showed complete remission in all outcomes. Two patients with partial remission in proteinuria were discontinued at their own request. In these patients, proteinuria decreased from 12.6 AE 0.42 g/ day at start of IAS therapy to 0.9 AE 0.01 at start of prolonged IAS to finally 0.64 AE 0.63 at EoO, while disease activity and anti-dsDNA levels were within remission limits (Pat. #9 and #10). One additional patient met remission criteria in the secondary outcomes, but closely missed remission in proteinuria after showing a decrease from 11.1 g/day (at start of IAS) to 5.6 (after 12 months) to 1.2 at EoO (Pat. #5, Figure 2 ).
Only one patient did not respond and was discontinued after a major renal flare (Pat. #7, Figure 2 ). This highly active patient was included in the IAS program when she experienced new onset CNS and renal SLE. After 3 months, proteinuria remained high (3.4 g/24 h), but we observed an R20 in the secondary outcomes (mainly due to the amelioration of her neurolupus) and continued IAS. After 1 year of therapy, she also responded with respect to proteinuria and met the inclusion criteria for prolonged IAS. After showing stable disease for an additional 3 years, she experienced a major renal flare. Before that, the patient had adherence issues and did not return regularly for her scheduled IAS therapy; in addition, she had stopped all her oral therapy (MMF, glucocorticoids and ACE inhibitors). Despite administration of IVCP, she progressed to renal failure.
Within 6.4 years of prolonged IAS, damage score SLICC changed slightly from 2 AE 1 to 3 AE 1 (P ¼ 0.02), which likely reflects late manifestations of the inflammatory processes before sustained stabilization of disease activity could achieved.
Analyses in patients treated for 10 years. Four patients completed 10 years of IAS therapy ( Figure 1 and Table 3 ): All reached full remission in major outcome proteinuria. Mean proteinuria steadily improved from 8.2 AE 4.2 g/day (at start of IAS) to 3.8 AE 3.0 after 1 year (P < 0.05). Under prolonged IAS, it further decreased to 1.3 AE 1.0 (after 5 years) and to 0.3 AE 0.2 (after 10 years) (P = 0.03 compared to absolute baseline at start of IAS and P = 0.09 compared to start of prolonged IAS), while serum albumin, creatinine and creatinine clearance were stable within normal ranges (data not shown). In addition, all patients reached remission in global disease activity (SLEDAI decreased from 4 AE 1 to 1 AE 1; P < 0.01) and pretreatment anti-dsDNA levels (from 35 AE 17 to 18 AE 6 IU/mL, P ¼ n.s.). Thus, all patients had achieved full remission in all outcomes, even though the frequency of IAS was slowly reduced (Figure 1 and Table 3A) .
Glucocorticoids, immunosuppression and additional treatment. All patients received glucocorticoids at decreasing dose during the first year of IAS (from 42.4 AE 33.6 to 9.2 AE 2.9 mg/day, P < 0.01). In 10 of 11 patients, the mean daily dose was reduced or kept stable under prolonged IAS leading to reduction from 9.63 AE 2.7 to 6.7 AE 3.0 mg/day, P ¼ 0.001. In Pat. #7, glucocorticoids were increased in order to cope with a major renal flare (Table 4) .
Within 3 months of IAS therapy, IVCP could be terminated in all respective patients and patients were switched to AZA or MMF. One additional patient under oral cyclophosphamide (Pat. #4) was switched to MMF, as were Pat. #1 and Pat. #2 when severe leucopenia resolved. At the start of prolonged IAS, all but two patients had stable oral immunomodulation; but also in these two patients (Pat. #5 and #10), we found a decrease in proteinuria (from 11.7 AE 0.8 g/day at start of IAS to 3.3 AE 3.3 after 12 months to 1.0 AE 0.4 at EoO) and a complete remission in SLEDAI and anti-dsDNA abs at EoO (Table 4) . Responses to prolonged IAS therapy. At the EoO, 10 (55%) patients under prolonged IAS showed a complete remission in all three outcome variables. Two patients in partial remission with respect to the primary outcome proteinuria were discontinued at their own request after showing a sustained response (Pat #9 and 10; proteinuria 0.59 and 0.68 g/day, respectively). In these patients, activity and dsDNA levels met the remission criteria. One additional patient showed a major response without completely reaching remission criteria at the EoO, although proteinuria was reduced by >70% (R70) compared to start of prolonged IAS (#5). One patient did not respond and was discontinued after a major renal flare (#7). Therapy with ACE inhibitors or AT-II-RA was kept constant (Table 4) ; one patient under ACE-inhibitors was switched to AT-II-RA due to side effects. Proteinuria decreased also in a patient without ACE inhibitors nor AT-II-RA (Pat. #4).
Prolonged IAS is well tolerated with respect to infections and adverse events. Infections have been rare under prolonged IAS (Table 5 ) and similar in frequency as in moderately active patients without IAS therapy treated at our centre (who had 0.1 severe and 0.05 mild infection per patient year [28] ). Neither the sites of infections nor their frequency at any particular site differed from previous observations in SLE [28, 47] . In contrast to previous findings in plasma exchange, viral infections were uncommon and mild; two-third of viral infections were due to Herpes simplex (Table 5) .
In our cohort, there was no procedure-related need for the application of blood products, even in patients subjected to extended courses of IAS. Indeed, compared with plasma exchange, IAS enables treatment of extended plasma volumes without the need to substitute fresh frozen plasma, albumin or coagulation factors [19, 26, 27] . IAS was routinously done via venovenous accesses punctures. Even prolonged IAS did not lead to venous complications, in line with the existing literature [48] . We did not observe orthostatic or anaphylactic dysregulation, tumours or malignancies (Table 5) .
Discussion
Extracorporeal therapies are a rescue strategy in critically ill SLE patients when conventional strategies have failed or are contraindicated [49] . Since IAS is still experimental, those patients finally undergoing IAS are characterized by active and progressive SLE resistant to conventional treatment, including cyclophosphamide. Thus, interpreting therapeutic effects in these patients on a background of previous immunosuppressive therapy is difficult. To cope with this limitation, we followed patients for up to 10 years and focused on proteinuria as a main feature of renal SLE; we also observed disease activity as indicated by both SLE-DAI and anti-dsDNA levels. In order to analyse efficacy of treatment, we used the patients' own data obtained before they underwent IAS as their respective baseline (so patients served as their own controls) and applied clinically reasonable remission criteria.
Under short-term IAS, proteinuria, disease activity and anti-dsDNA levels decreased. In order to address the question whether the prolongation of IAS beyond 1 year has additional therapeutic value, we focused on those patients who had not reached remission with respect to proteinuria and observed a further decrease beyond the original decline seen after the first year of therapy. In addition, disease activity stabilized as indicated by a further reduction in activity scores, anti-dsDNA levels and numbers of flares. Although the course of disease in SLE varies, these positive effects are likely induced by IAS itself since concomitant therapy was kept constant or reduced and two patients without any immunomodulation also responded well to IAS monotherapy. Since the prolongation of IAS offered additional therapeutic benefit in patients with proteinuria, it appears a reasonable strategy to extend IAS therapy in such patients.
At the EoO, 55% of these previously therapy-refractory patients (and all patients undergoing full 10 years of therapy) reached complete remission in all three outcomes and an additional 27% reached at least partial remission, while only one patient was a nonresponder. As discussed, compliance issues may have contributed to the poor outcome in this patient who had a sufficient (albeit delayed) response after 1 year of IAS.
Prolonged IAS for as long as 10 years with up to 324 IAS sessions per patient appeared safe with respect to infections, malignancies and other unwanted reactions. In addition, IAS was safely applied in a patient with high disease activity, renal SLE and active tuberculosis [19] .
The major limitation of our study is its observational rather than controlled nature. However, the patients studied were refractory to immunosuppression (or could not be given immunosuppressives) and were highly improved by IAS. We used objective measures such as proteinuria and anti-dsDNA levels which all improved or partly normalized, an observation not usually made in patients with severe renal disease. Thus, while uncontrolled, this study can be regarded as hypothesis generating and should be followed by a controlled trial in a similar group of patients under careful observation by a data-monitoring board.
In summary, IAS offers an alternative therapeutic strategy in severe, active refractory SLE not only in the short-term but also has additional beneficial effects in the long-term use. IAS was safe and effective in our group of patients, but in order to define its future role in SLE, controlled trials are warranted.
